Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte antigen 6 family member D (LY6D)
- Target
- LY6D
- Molecular classification
- Other (GPI-anchored cell surface protein), Ly-6/uPAR family
01
Overview
Lymphocyte antigen 6 family member D (LY6D), historically known as the E48 antigen, is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein predominantly expressed in squamous epithelia and associated squamous cell carcinomas. It belongs to the Ly-6/uPAR family and is localized to human chromosome 8q24.3. LY6D is involved in keratinocyte cell-cell adhesion and marks the earliest stage of B-cell specification, distinguishing between B and T cell lineages during lymphocyte development. It has high clinical relevance as a therapeutic and diagnostic target for antibody-based therapy in squamous cell carcinoma, especially of the head and neck, due to its restricted expression profile and functional involvement in tumor biology[1][2][3][4][5][7][9][10].
- Other names
- E48 antigenLy-6DE48Lymphocyte antigen 6DLymphocyte antigen 6 complex locus Ddesmoglein III (historical name)
02
Mechanism of action
Antibody-dependent targeting for immunotherapy, exploiting overexpression on squamous carcinoma cells
03
Biological functions
Cell-cell adhesion in keratinocytesSpecification marker in early B-cell versus T-cell lymphocyte specificationInvolved in squamous epithelial differentiation and tumor progression
04
Disease associations
Cancer (notably squamous cell carcinoma, including head and neck squamous cell carcinoma)Marker of squamous epithelial malignancies
05
Safety considerations
Potential off-target effects given expression in some normal squamous epitheliaSafety not fully established for all antibody-based therapeutics; expected on-target, off-tumor effects due to restricted but not exclusive tumor expression
06
Interacting drugs
Monoclonal antibody E48 (therapeutic antibody developed for targeting minimal residual disease in squamous cell carcinoma)
07
Biomarkers
Used as a marker for squamous cell differentiation and squamous cell carcinoma in patient selection and diagnosticsImmunodetection in tumors for therapy stratification
Beyond the preview
Go deeper on Lymphocyte antigen 6 family member D (LY6D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lymphocyte antigen 6 family member D (LY6D).